Chi‐Chung Chan

Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes

George R. Lankas, Barbara Leiting, Ranabir Sinha Roy et al. · Diabetes · 2005 · 490 citations · Full text

Diabetes Management, Pharmacological Study, Biochemistry +15

Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2

Denis Riendeau, M. David Percival, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 456 citations · Full text

The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

Petpiboon Prasit, Z Wang, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 426 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Active Cyclooxygenase-2 Inhibitor +10

Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles

Chi‐Chung Chan, S. Boyce, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 397 citations · Full text

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor

Denis Riendeau, M. David Percival, S. Boyce et al. · British Journal of Pharmacology · 1997 · 326 citations · Full text

Pge2 Production, Chemoprevention Strategy, Immunology +16